Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

immatics Appoints Dr Rainer Kramer as CBO

Published: Thursday, April 12, 2012
Last Updated: Thursday, April 12, 2012
Bookmark and Share
Dr. Kramer will lead immatics’ business development unit.

immatics biotechnologies GmbH has announced the appointment of Dr. Rainer Kramer as Chief Business Officer (CBO) with immediate effect.

In this newly created role, Dr. Kramer will lead immatics’ Business Development Unit in order to create optimal value from the Company’s pipeline of therapeutic cancer vaccines.

Dr. Kramer has many years of business development experience within the pharmaceutical industry. He joins from Signature Diagnostics, an oncology diagnostics company where he was CBO.

Before that, he was Vice President Business Development at Jerini AG, where he was responsible for all licensing, partnering, and alliance management activities, and played a key role in the sale of the Company to Shire in 2008.

Before joining Jerini, he held various business development and research positions at MorphoSys AG, Martinsried, and Amgen Inc.

Dr. Kramer holds a Diploma in Molecular Biology from the University of Regensburg and a PhD from the Max-Planck-Institute for Neurobiology.

“Rainer’s appointment is a further important step in advancing our business strategy aimed at maximizing the potential of our TUMAP-based therapeutic cancer vaccine pipeline”, said Paul Higham, CEO of immatics.

Higham continued, “The positive clinical results that we have already generated with our lead products IMA901, for advanced renal cancer, and IMA910, for advanced colorectal cancer, highlight our potential to make a real difference to the management of these difficult to treat cancers. Rainer’s strong business and deal-making experience will be a great asset as we seek partners where appropriate to help us to progress our vaccine candidates to market.”

Rainer Kramer said: “The impressive data with IMA901 and IMA910 confirm the tremendous potential of this novel class of therapeutic vaccines. I am delighted to be joining immatics at such an exciting time and look forward to making a significant contribution to the successful implementation of the Company’s corporate strategy, which is expected to deliver significant shareholder value and much improved treatment options for cancer patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines
Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC).
Thursday, October 16, 2014
immatics Receives €22 Million Final Tranche of Series D Fundraising
Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics’ Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies.
Thursday, July 17, 2014
Immatics to Continue Work on Vaccine (IMA950) for Glioblastoma
A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a trial conducted by Cancer Research UK.
Thursday, April 24, 2014
immatics Closes €34 Million Financing
immatics’ lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015.
Tuesday, October 15, 2013
Professor Dr Hans-Georg Rammensee Awarded the Bayer Hansen Family Award 2013
Prestigious Hansen Family Award recognizes Hans-Georg Rammensee’s pioneering scientific research activities.
Friday, March 08, 2013
immatics Presents Encouraging Overall Survival Data from a Phase 2 Study in CRC
T-cell responses to the IMA910 colorectal cancer vaccine peptides show a clear correlation with longer overall survival.
Monday, June 04, 2012
immatics Wins 2012 TiE50 Award
immatics chosen as a leading company in the life sciences category by the world's largest entrepreneurial network.
Friday, May 25, 2012
immatics Presents Positive Phase II Results with IMA910 in CRC Patients
Study shows a consistent association between immune response to IMA910 and all clinical endpoints and an excellent tolerability profile.
Wednesday, January 25, 2012
Scientific News
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
Shining A Light On Bladder Cancer
Researchers scrutinize patterns of mutations in bladder tumor genomes, gleaning insights into the roles of DNA repair and tobacco-related DNA damage.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Genetic Variant May Help Explain Why Labradors Are Prone To Obesity
A genetic variation associated with obesity and appetite in Labrador retrievers – the UK and US’s favourite dog breed – has been identified by scientists at the University of Cambridge. The finding may explain why Labrador retrievers are more likely to become obese than dogs of other breeds.
How Scientists Use DNA to Track Disease Outbreaks
They’re the top questions on everyone’s mind when a new disease outbreak happens: where did the virus come from? When did this happen? How long has it been spreading in a particular country or group of people?
Genetic Risk Factors of Disparate Diseases Share Similar Biological Underpinnings
Penn Institute for Biomedical Informatics and colleagues identify "roadmap" of disease mechanisms to identify candidate drug targets.
Stem Cells Know How to Unwind
Research led by the Babraham Institute with collaborators in the UK, Canada and Japan has revealed a new understanding of how an open genome structure supports the long-term and unrestricted developmental potential in embryonic stem cells.
Childhood Asthma Research Receives $2M
Research into the impact of a child’s upbringing and social and physical environments on the development of asthma will receive $2 million to tackle the condition that affects as many as one in three Canadians.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!